Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Ortoma

14.45 SEK

-0.69 %

Less than 1K followers

ORT B

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.69 %
-8.54 %
-35.49 %
+9.89 %
+55.71 %
+47.45 %
+23.60 %
-39.73 %
+372.23 %

Ortoma operates in the medical technology sector. The company develops surgical systems for implant treatment. The technology is based on 3D models and is mainly used to plan and position implants such as hip, knee and back surgery. The products are used by orthopaedic surgeons and in various surgeries, and the business is based on research and development within the field. The company has its headquarters in Gothenburg.

Read more
Market cap
535.86M SEK
Turnover
80.17K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2.
2026

Annual report '25

21.5.
2026

General meeting '26

All
Press releases
ShowingAll content types
Press release11/5/2025, 9:41 AM

DNB Carnegie Access: Ortoma: In line with our expectations – Q3 initial comment

Ortoma
Press release10/16/2025, 12:25 PM

DNB Carnegie Access: Ortoma: Secure orders from Japan

Ortoma
Press release9/11/2025, 5:02 AM

DNB Carnegie Access: Ortoma: Shaping the future of orthopaedics with AI– initiating coverage

Ortoma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release2/28/2025, 8:10 AM

Redeye: Ortoma Q4’2024 - Continued strong progress at year-end

Ortoma
Press release11/4/2024, 9:22 AM

Redeye: Ortoma Q3’2024 - Positive outlook and finances in focus

Ortoma
Press release7/19/2024, 6:47 AM

Redeye: Ortoma - Creating a good foundation for growth

Ortoma
Press release5/24/2024, 7:06 AM

Redeye: Ortoma - Heading in the right direction

Ortoma
Press release2/21/2024, 7:03 AM

Redeye: Ortoma Q4’23 - A very exciting year for Ortoma

Ortoma
Press release10/27/2023, 7:35 AM

Redeye: Ortoma - Following the set path

Ortoma
Press release9/26/2023, 6:55 AM

Redeye: Ortoma - A game changer

Ortoma
Press release8/23/2023, 12:02 PM

Redeye: Ortoma Q2 2023 - Ignition engaged

Ortoma
Press release8/14/2023, 5:55 AM

Redeye: Ortoma - Preplanning for success

Ortoma
Regulatory press release12/6/2022, 7:31 AM

Ortoma agrees on term sheet for development and distribution of customized version of OTS Hip

Ortoma
Regulatory press release11/9/2022, 7:30 AM

Strong interest in Ortoma's new 3D modelling concept

Ortoma
Regulatory press release11/7/2022, 8:30 AM

Ortoma completes training session for surgeons ahead of pilot period in Japan

Ortoma
Regulatory press release10/31/2022, 9:01 AM

Ortoma presents breakthrough 3D concept for orthopedic surgery at AAHKS Annual Meeting in Dallas

Ortoma
Regulatory press release3/17/2021, 9:24 AM

Ortoma Submits Application for CE-mark of Spine Module

Ortoma
Regulatory press release3/16/2021, 9:47 AM

Ortoma Obtains Granted Patent in the USA

Ortoma
Regulatory press release2/25/2021, 10:34 AM

Ortoma launches new website highlighting market leading AI-assisted surgical solutions

Ortoma
Regulatory press release12/14/2020, 9:30 AM

Ortoma launches OTS 5 according to plan

Ortoma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.